ReviewImmunological reviews2025
Bridging pDCs and cDCs: The Identity of Transitional Dendritic Cells.
Review in Immunological reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Establishment of a novel immortalized cell line derived from porcine plasmacytoid dendritic cells.In vitro cellular & developmental biology. Animal · 2026Article
- Dendritic-cell diversity in equine blood revealed by single-cell transcriptomics.Discovery immunology · 2026Article
- The plasmacytoid dendritic cell paradox in cancer: impaired type I interferon responses in a nucleic acid-rich tumor microenvironment.Frontiers in immunology · 2026Review
- Bridging pDCs and cDCs: The Identity of Transitional Dendritic Cells.Immunological reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Transitional dendritic cells (tDCs) have emerged as a compelling addition to the dendritic cell (DC) network-a hybrid subset that bridges plasmacytoid (pDC) and conventional (cDC) lineages, particularly conventional type 2 DCs (cDC2s). First identified through high-dimensional single-cell profiling, tDCs combine features of both pDCs and cDC2s yet follow a distinct developmental trajectory with unique effector functions. Although ontogenetically related to pDCs, tDCs do not produce type I interferon but instead mount a robust IL-1β response upon pathogen sensing, positioning them as rapid initiators of innate inflammation. tDCs also mirror cDC2s in their ability to capture antigen and prime naïve CD4
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.